Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	2 Months Ended	12 Months Ended
	Mar. 07, 2013	Dec. 31, 2012	Dec. 31, 2011
Significant Accounting Policies [Line Items]
Revenue from pharmaceutical clients		$ 6,852,536	$ 10,106,263
Accounts receivable, net of allowance for doubtful accounts		5,373,023	4,047,059
Accounts receivable, allowance for doubtful accounts		991,990	838,750
Bad debt expense		1,351,592	1,299,633
Amortization period of software development costs		5 years
Line of credit agreement date		Jul. 14, 2011
Line of credit, expiration date	Mar. 07, 2015
Line of credit, fee for unused portion	0.25%	0.375%
Line of credit, minimum quick ratio	1.5
Line of credit, maximum borrowing capacity	2,000,000	2,000,000
Line of credit, borrowing base percentage of pharmaceutical accounts receivable		80.00%
Line of credit, interest above prime rate		1.00%
Line of credit, interest charged		5.00%
Line of credit, amount drawn		1,000,000	1,000,000
Required minimum bank balance	4,000,000	4,000,000
Bank line of credit, over-advance amount required to be repaid		298,000
Advertising costs		13,788	97,971
Insurance coverage per depositor at each financial institution		250,000
Uninsured foreign cash balance		7,757
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage		71.00%	75.00%
Letter of Credit [Member]
Significant Accounting Policies [Line Items]
Line of credit, maximum borrowing capacity		500,000
Clinical [Member]
Significant Accounting Policies [Line Items]
Payment period from the date of invoice		45 days
Accounts receivable, net of allowance for doubtful accounts		2,549,665	1,701,836
ResponseDX [Member]
Significant Accounting Policies [Line Items]
Accounts receivable, net of allowance for doubtful accounts		2,823,358	2,345,223
Accounts receivable, allowance for doubtful accounts		991,990	838,750
Bad debt expense		$ 1,351,592	$ 1,299,633